Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Prognosis of Myelodysplastic Syndromes (MDS) in Patients in the Age of 80 Years and Older: Data from the Regular Care MDS Registry in Germany

H. Tilman Steinmetz, MD, Roja Wahdat, Burkhard Haastert, PhD, Annette Sauer, MD, Bernd Lathan, MD, Christian Lerchenmüller, MD, Hans Tesch, Professor, Ulrich Germing, Stephan Schmitz, Professor

Blood (2016) 128 (22): 4333.

https://doi.org/10.1182/blood.V128.22.4333.4333

Published: 2016

Journal Articles

Treatment Outcome of Patients with Myelodysplastic Syndromes (MDS) in Regular Care: Incidence of IPSS Risk Groups and Different Therapies in the German Outpatient MDS Registry

H. Tilman Steinmetz, MD, Isolde Böttger, Bernd Lathan, MD, Annette Sauer, MD, Enno Moorahrend, MD, Kai Severin, MD, Ulrich Germing, MD, Stephan Schmitz, MD, Norbert Gattermann, MD

Blood (2014) 124 (21): 5601.

https://doi.org/10.1182/blood.V124.21.5601.5601

Published: 2014

Journal Articles

Incidence, Treatment and Course Of Disease Of Patients With del5q Myelodysplastic Syndrome (MDS) In The “pre-lenalidomide” Era In Germany. Data From The German Outpatient MDS Registry

H. Tilman Steinmetz, MD, Isolde Böttger, Annette Sauer, MD, Dominick Linck, MD, Kai Severin, MD, Ulrich Germing, MD, Norbert Gattermann, MD, Stephan Schmitz, MD

Blood (2013) 122 (21): 1540.

https://doi.org/10.1182/blood.V122.21.1540.1540

Published: 2013

Journal Articles

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Julie Schanz, MD, Friederike Braulke, Katayoon Shirneshan, PhD, Kathrin Nachtkamp, MD, Ulrich Germing, MD, Stephan Schmitz, MD, Peter Haas, MD, Michael Lübbert, MD, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2784.

https://doi.org/10.1182/blood.V122.21.2784.2784

Published: 2013

Journal Articles

Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia

H. Tilman Steinmetz, Antonis Georg Tsamaloukas, MD, PhD, Stephan Schmitz, Jörg Wiegand, Robert Rohrberg, Jochen Eggert, Heidi Eustermann, Hans-Werner Tessen, Lothar Thomas

Blood (2008) 112 (11): 4578.

https://doi.org/10.1182/blood.V112.11.4578.4578

Published: 2008

Journal Articles

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, MD, PhD, Martin H. Dreyling, MD, PhD, Hartmut Eimermacher, MD, Hans-Peter Boeck, MD, Michael Pfreundschuh, MD, PhD, Bernd Metzner, MD, Roland Fuchs, MD, PhD, Bernhard Woermann, MD, PhD, Lorenz H. Truemper, MD, PhD, Georg Hess, MD, Hannes Wandt, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Ernst-Dietrich Kreuser, MD, PhD, Joerg Schimke, MD, H.-J. Weh, MD, PhD, Stephan Schmitz, MD, PhD, W. Schmiegel, MD, PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2004) 104 (11): 162.

https://doi.org/10.1182/blood.V104.11.162.162

Published: 2004

Journal Articles

Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas - Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group ( GLSG ).

Rudolf Weide, Hubert Koeppler, Jochen Heymanns, Joerg Thomalla, Georg Hess, Heinhold Gamm, Ali Aldaoud, Stephan Schmitz, Ursula Haak, Dirk Plewe, Oswald Burkhard, Bernd Gaede, Fokke Hinrichs, Karl-Heinz Pflueger, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann

Blood (2004) 104 (11): 2482.

https://doi.org/10.1182/blood.V104.11.2482.2482

Published: 2004

NARROW

Prognosis of Myelodysplastic Syndromes (MDS) in Patients in the Age of 80 Years and Older: Data from the Regular Care MDS Registry in Germany

Treatment Outcome of Patients with Myelodysplastic Syndromes (MDS) in Regular Care: Incidence of IPSS Risk Groups and Different Therapies in the German Outpatient MDS Registry

Incidence, Treatment and Course Of Disease Of Patients With del5q Myelodysplastic Syndrome (MDS) In The “pre-lenalidomide” Era In Germany. Data From The German Outpatient MDS Registry

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas - Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group ( GLSG ).

Email alerts

ASH Publications

American Society of Hematology

Prognosis of Myelodysplastic Syndromes (MDS) in Patients in the Age of 80 Years and Older: Data from the Regular Care MDS Registry in Germany

Treatment Outcome of Patients with Myelodysplastic Syndromes (MDS) in Regular Care: Incidence of IPSS Risk Groups and Different Therapies in the German Outpatient MDS Registry

Incidence, Treatment and Course Of Disease Of Patients With del5q Myelodysplastic Syndrome (MDS) In The “pre-lenalidomide” Era In Germany. Data From The German Outpatient MDS Registry

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Bendamustine/Mitoxantrone/Rituximab (BMR): A Very Effective and Well Tolerated Immuno-Chemotherapy for Relapsed and Refractory Indolent Lymphomas - Results of a Multicentre Phase-II-Study of the German Low Grade Lymphoma Study Group ( GLSG ).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only